Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

M. van Gelder, M. H. van Oers, W. G. Alemayehu, M. C. J. Abrahamse-Testroote, J. J. Cornelissen, M. E. Chamuleau, P. Zachee, M. Hoogendoorn, M. Nijland, E. J. Petersen, A. Beeker, G-J Timmers, L. Verdonck, M. Westerman, O. de Weerdt, A. P. Kater

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)799-806
JournalBone Marrow Transplantation
Volume51
Issue number6
DOIs
Publication statusPublished - Jun 2016

Cite this

van Gelder, M., van Oers, M. H., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E., Zachee, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., Beeker, A., Timmers, G-J., Verdonck, L., Westerman, M., de Weerdt, O., & Kater, A. P. (2016). Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplantation, 51(6), 799-806. https://doi.org/10.1038/bmt.2016.9